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Abstract
Background: Obesity is the most common health problem in developed countries. Recently,
several physicians' organizations have issued recommendations for treating obesity to family
physicians, including instructions in nutrition, physical activity and medications. The aim of this study
was to examine if effective weight-reducing treatment can be given by a family physician. It
compares regular treatment with intensive treatment that include close follow-up and orlistat
treatment.
Methods: The study was conducted in three primary care clinics. 225 patients were divided into
three groups according to their choice. Group A received a personal diet with fortnightly meetings
with the family physician and dietitian and orlistat treatment. Group B received a general diet,
monthly meetings with the family physician only and orlistat treatment. Group C received a
personal diet, monthly meetings with the dietitian only and no drug treatment. The primary
endpoint was reduction of at least 5% of the initial weight during the study period.
Results: A greater percentage of patients in group A achieved their weight reduction goals than in
other groups (51%, 13% and 9% in groups A, B and C, respectively, p < 0.001). There was a
significant reduction in triglycerides in all groups, a significant reduction of low density lipids (LDL)
in groups A and B and no significant difference in high density lipids (HDL) in any group.
Conclusions: Significant weight reduction was obtained in a family physician setting. Further
research is needed to evaluate if, by providing the family physician with the proper tools, similar
success can be achieved in more clinics.
Background
Obesity is the most common health problem in devel-
oped countries [1]. It is a chronic disease and should be
treated as such. Its prevalence is increasing worldwide [2].
In the United States, it is estimated that 64% of the adult
population is either overweight or obese with a body mass
index (BMI; kg/m2) above 25 [3]. The rate of obesity is
increasing [4] and has risen by more than 75% in the USA
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since 1980 [5]. In 2001, the prevalence of obesity (BMI ≥
30) was 20.9% vs 19.8% in 2000, an increase of 5.6% [6].
In Israel, according to a survey of the Nutrition Depart-
ment of the Ministry of Health, 55% of adult (ages 25–64)
women and 59% of adult men have a BMI above 24.9 [7].
Obesity is associated with increased prevalence of many
serious chronic diseases such as diabetes mellitus, hyper-
tension, dyslipidemia, and coronary heart disease [8,9]. It
may be responsible for approximately 300,000 deaths in
the USA per year [10]. In the Nurses Health Study, the 14-
year mortality rate for women with a BMI greater than 32
was more than double that of women with a BMI of less
than 19 [11]. Obesity now ranks second only to smoking
as a cause of preventable death but, soon, obesity may sur-
pass smoking as the leading cause of preventable death in
the USA [12]. In the USA, 19% of deaths from coronary
disease and 62% of deaths from diabetes can be attributed
to obesity [13]. The risk of death from all causes increases
in moderately and severely overweight men and women
of all age groups [14].
Diet and exercise have limited effectiveness on long-term
maintenance of weight loss [15]. Within five to seven
years, 95% of all patients regain the lost weight or more
[16]. Pharmacotherapy in combination with a reduced
energy diet improves long-term efficacy [17]. Loss of 5–
10% of their initial body weight substantially improves
the health of obese patients and modifies their cardiovas-
cular risk factors [8,18]. Despite growing information on
the pathophysiology of obesity and its high prevalence,
obesity and obesity-related diseases are still under-diag-
nosed and untreated by family physicians [19]. Most fam-
ily physicians cite lack of time, resources, reimbursement
from insurance companies, or knowledge of effective
interventions as significant barriers [20].
The intervention of primary physicians during a ten
minute physician/patient encounter and telephone con-
sultation with a community dietitian resulted in a signifi-
cant decrease in the weight of patients [20]. Recently,
several physicians' organizations have issued recommen-
dations for treating obesity to family physicians, includ-
ing instructions in nutrition, physical activity and
medications. Such recommendations were based on a
number of studies that proved the effectiveness of family
physician weight-reduction programs, when based on the
readiness of patients to make necessary lifestyle changes
and use of appropriate techniques to increase the willing-
ness of the patient to make necessary changes [21-24].
The purpose of this study was to examine if more efficient
and effective weight-reducing treatment can be given in
the family doctor setting. The study compare a non-phar-
macological intervention with drug intervention (orlistat)
and compare regular management with more intensive
family physician based management..
Methods
Study design
The study was conducted in three primary care clinics in
an urban area in central Israel. The family physicians who
took part in this study participated in 80 hours CME
course dealing with obesity treatment in Israel.
The patients were divided into three groups according to
their choice. Patients in groups A and B were treated with
orlistat at 120 mg TID. Orlistat (Xenical ®) is a lipase
inhibitor for obesity management that acts by inhibiting
the absorption of dietary fats.
The patients in group A received in addition a personal
reduced-energy diet and met with a family practitioner
and a clinical dietitian once every two weeks. The personal
diet was created according to the daily schedule and pre-
ferred foods of the individual, emphasizing low-fat foods.
The patients received instructions regarding the impor-
tance of physical activity and, at each meeting, realistic
intermediate goals for achieving two or three small
changes in eating habits and physical activity, based on
the patient's desires, were determined. The obstacles to
change and ways to overcome them were discussed. Sup-
port, based on improvements in the patient's health
parameters such as an improvement in a blood test, was
given.
Some of the patients helped with self-criticism, by keeping
food and physical activity diaries and by grading their
own goal accomplishments. Patients were taught how to
resist temptation and reward themselves for success. We
also recruited the support and encouragement of the
patient's family. At each meeting, the time of the next
meeting was determined and it was emphasized that the
most important thing for the patients to do was to attend
the meetings, even if their goals were not achieved.
Group B patients were treated with 120 mg orlistat t.i.d., a
general formulated reduced-energy diet and follow-up by
the family physician once every four weeks for weighing
and prescription renewal.
In groups A and B, patients were asked at each meeting if
any side effects of orlistat appeared.
Patients in group C were given a personal low-calorie diet,
designed according to their preferences, and followed-up
by a clinical dietitian once a month.BMC Family Practice 2005, 6:5 http://www.biomedcentral.com/1471-2296/6/5
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The prescribed daily caloric intake was equal in the three
groups and was 1200 calories per day for women and
1500 calories per day for men.
Before the intervention, every patient received an explana-
tion of the three treatments, the importance of reducing
weight, and how excess weight affects their health. All
were instructed about the recommended rate of weight
loss and a final weight reduction goal of at least 5% of
their initial weight within half a year was established.
Patients who achieved the 5% reduction goal before the
end of the study could choose either to stop the interven-
tion or to complete the study period.
Patients
Obese (BMI > 30) patients of either sex or patients with a
BMI above 27 plus two or more cardiovascular risk fac-
tors, aged 20–75 years, were eligible for the study. Patients
were excluded if they were pregnant or lactating or if they
had any contraindication against using orlistat (chronic
malabsorption syndrome, cholestasis, pancreatic disease).
Before the intervention, patients underwent an initial
screening that included recording of a complete medical
history, measurement of vital signs, body weight and
height, and calculation of the BMI. Laboratory analysis
included a lipid profile. The readiness of the patient to
receive treatment was assessed. At the beginning of the
intervention, all participants were in the third stage of
readiness ("the preparation stage") according to the Tran-
stheoretical Model of Behavior Change.
An adverse event of any dose of orlistat was considered
serious if it resulted in death, was life-threatening,
required hospitalization, or resulted in significant
disability.
Efficacy measures
The main measure was weight loss. Each patient was
weighed during each meeting. The primary endpoint was
reduction of at least 5% of the initial weight during the
study period (six months). Achievement of this goal was
defined as successful treatment. Another measure was
improvement in the lipid profile.
The second lipid profile was done to half of the patients,
only those who had dyslipidemia in the first profile had
been offered a second profile.
Statistical analysis
Data on patients' background and weight-reduction
results between groups were compared using the Chi
square test. Continuous data of the groups, i.e., measure-
ments at the beginning of the study and continuous back-
ground data, were compared using one-way tests
(ANOVA). When significant statistical differences were
found among the three groups, the Tukey Post Hoc test
was used to examine the statistical difference between
each group of two. ANCOVA was also used and, if there
was a difference amongst the groups, the significance (for
the measured parameter) was checked using the Bonfer-
onni technique.
Results
Two hundred and twenty-five patients participated in the
study. Their demographic characteristics, history of cardi-
ovascular disease, and initial lipid profile are shown in
Table 1. There were no significant differences between
groups in average age, initial BMI or gender of the partici-
pants. The average length of follow-up and the number of
meetings varied among groups. There were no cases of sig-
nificant side effects that required stopping orlistat treat-
ment of any of the participants.
Patient-reported adverse events in the orlistat-treated
groups were all related to the gastrointestinal tract. The
most commonly reported events were flatulence with dis-
charge (9.2%), fatty or oily stool with increased defeca-
tion (9.2%), feeling of fullness in the stomach (4.6%),
and constipation (1.7%). There were no statistically sig-
nificant differences in side effects between groups A and B.
In group A, 11 patients (17.7%) stopped the treatment for
the following reasons: cost of the medication (47%), lack
of time (33%), or dissatisfaction (20%). In comparison,
ten patients (8.9%) in group B stopped the treatment,
mainly because of the cost of the treatment (65%) or low
motivation (23.5%). The reasons for stopping treatment
significantly differed between groups A and B (p = 0.03).
The percentage of patients who attained their weight
reduction goals was largest in group A where patients
received orlistat and intense follow-up, in addition to a
personally-designed diet (Fig. 1). Changes in lipid profiles
are shown in Table 2. The treatment resulted in a signifi-
cant reduction in triglyceride levels in all groups, a signif-
icant reduction of low density lipoproteins (LDL) in
groups A and B and no significant difference between ini-
tial and final high density lipoproteins (HDL) in any
group.
Patients in Group A reduced 5.12 kg (range of 5–8 Kg.) of
their initial body weight, patients in Group B reduced 7.8
kg (range 10–12 Kg.) from their initial body weight and
patients in Group C reduced 3.12 kg (range 5–6 Kg.) of
their initial body weight.
Discussion
Obesity is a worldwide problem. Treatment of a patient
for obesity involves two processes: evaluation of the sever-
ity of the obesity and general health condition of theBMC Family Practice 2005, 6:5 http://www.biomedcentral.com/1471-2296/6/5
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patient, and management which includes guidance in
how to gradually reduce weight and maintain the new
weight together with imparting healthy lifestyle habits
and keeping track of improvement.
In this study, we examined weight-reduction techniques
that can be carried out in the setting of a community fam-
ily practice. Intense treatment, combining frequent coun-
seling by the family physician and a dietitian with
medications (group A), resulted in the best weight reduc-
tion and lipid profile improvement in the short period of
this study, as was reported earlier in special weight reduc-
tion clinics [25-27]
The effectiveness of interventions in primary care setting
are controversial [28-30]. Beermann et al [28] in a com-
munity survey of 792 patients found that Orlistat was not
prescribed according to the approved indication in the
majority of cases. The dropout rate was high and most
patients had minor gain from the treatment. Linne et al
[29] noted that success rate of Orlistat in primary-care
practice is limited by failure to follow prescribing recom-
mendations. A simple questionnaire to 70 patients
revealed that in many cases the referral physician had not
observed basic rules and regulations, nor given appropri-
ate information on Orlistat use.
Hauptman et al [30] in a study conducted in seventeen
primary care centers in the United States. The study indi-
cates that orlistat is an effective adjunct to dietary inter-
vention in the treatment of obesity in primary care
settings.
There are many advantages to a program involving coop-
eration between the family physician and the dietitian.
The family physician is acquainted with the patient for a
longer time than a dietitian. The physician is familiar with
the patient's health condition, medications taken by the
patient, the patient's environment and lifestyle and can
recommend a treatment suitable to the patient's personal-
ity and lifestyle. The family physician is knowledgeable
about weight-reducing drugs and possible side effects. The
patient trusts and has confidence in the family doctor.
Together with the dietitian, a personal diet appropriate to
the drug treatment can be created.
Obesity is a chronic disease. The physician and the patient
must recognize that obesity treatment is a prolonged proc-
ess that extends a lifetime. Since family physicians are usu-
ally familiar with their patients as well as with the
patient's family and environment for many years, family
physicians know what changes the patient can achieve.
They can recruit family members to support the necessary
lifestyle changes. Also, because of their training, family
Table 1: Participants' demographic data, initial lipids profile, by treatment group
Group A Group B Group C P* value
Number of patients 62 112 51
Age (years +/- SD) 47.3 ± 11 46.8 ± 12 51 ± 9.6 NS
Gender (% female) 71 74 61 NS
Ischemic heart disease (%) 0 4 0 NS
Hypertension (%) 44 51 27 P < 0.05
Diabetes mellitus (%) 9 18 20 NS
Dyslipidemia (%) 16 38 66 P < 0.001
Initial body weight
Initial body mass index (BMI; kg/m2 +/- SD) 33 ± 3.8 34 ± 4.4 31 ± 3.6 P < 0.01
34 > 31(B > C)
Initial triglycerides (mg/dl, +/- SD) 170 ± 53 184 ± 49 255 ± 205 P < 0.01
170 <255> 183
(A < B > C)
Initial low density lipoproteins (LDL; mg/dl, +/- SD) 150 ± 30 156 ± 36 152 ± 44 NS
Initial high density lipoproteins (HDL; mg/dl, +/- SD) 42 ± 7.0 44 ± 6.7 47 ± 14.9 NS
Average length of treatment (weeks, +/- SD) 13 ± 12.0 9 ± 4.7 23 ± 12 P < 0.001
23 > 13 > 9
(C > A > B)
Number of meetings with physician/dietitian (+/- SD) 4.3 ± 2.0 3.5 ± 1.5 5.2 ± 2.9 P < 0.001
5.2 > 3.5 (C > B)
NS = Not significant.
Group A – Orlistat, a personal reduced-energy diet and a meeting with a family practitioner and a clinical dietitian once every two weeks.
Group B – Orlistat, a general formulated reduced-energy diet and follow-up by the family physician once every four weeks.
Group C – a personal low-calorie diet and follow-up by a clinical dietitian once a month.
* When significant statistical differences were found among the three groups, we examined the statistical difference between each group of two.BMC Family Practice 2005, 6:5 http://www.biomedcentral.com/1471-2296/6/5
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physicians are the most suitable professional to holisti-
cally treat obesity and its complications.
There were several limitations in our study. One limita-
tion was the non-random division of patients into groups
A, B and C. It is possible that the patients who chose drug
treatment differed from those who chose a diet only. Per-
haps they were more ready for the weight-reduction proc-
ess and to expend money for the drug (in Israel, there is a
patient co-payment for medications). The rate of women
amongst the patients seeking treatment was higher than
the rate of men, as in other reports [26,27]. Hence, we
assume that our study represented the segment of the pop-
ulation more prone to try dieting and weight-reduction
programs. Ways to increase the number of men participat-
ing in weight-reduction programs must be found.
The study periods for groups A and B (which received orl-
istat) were shorter than for group C, partly because there
is significant co-payment for orlistat and partly because
the targeted weight had been achieved earlier. The drug
was well tolerated with minimal gastrointestinal side
effects.
The patients were treated by family physicians that were
orientated toward and trained in weight reduction.
Results might have been less successful with other physi-
cians. Hence, family physicians should be trained in the
subject by increasing both their knowledge and their treat-
Weight loss by treatment group* Figure 1
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ment skills. Healthcare funds must recognize the impor-
tance of weight reduction so that they will allocate the
necessary additional time and resources of their physi-
cians, clinics and multi-field staff.
This study evaluated only the weight reduction period.
Long-term results and whether or not the patient main-
tained the lifestyle change for a long period were not
examined. Further studies should examine the best pro-
gram for maintaining the new weight.
In conclusion, this study showed that within the setting of
the family practice it is possible to carry out an effective
program of weight reduction and achieve significant
weight loss. The addition of orlistat can further improve
results. We believe that by providing family physicians
with the proper tools, similar success can be achieved in
many more clinics.
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